Patents Assigned to Sangamo Therapeutics, Inc.
  • Compositions for linking DNA-binding domains and cleavage domains
    Patent number: 11920169
    Abstract: Disclosed herein are compositions for linking DNA binding domains and cleavage domains (or cleavage half-domains) to form non-naturally occurring nucleases with alternative configurations. Also described are methods of making and using compositions comprising these linkers.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: March 5, 2024
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Jeffrey C. Miller, David Paschon, Edward J. Rebar
  • IMPROVED PHARMACEUTICAL COMPOSITIONS CONTAINING ADENO-ASSOCIATED VIRAL VECTOR
    Publication number: 20240066146
    Abstract: The present invention provides compositions comprising a recombinant AAV and one or more pharmaceutically acceptable excipients. The compositions have improved stability and shelf life as compared to other AAV compositions.
    Type: Application
    Filed: December 17, 2021
    Publication date: February 29, 2024
    Applicants: Sangamo Therapeutics, Inc., Pfizer Inc.
    Inventors: Jessica Eileen Conner, Lindsey Anne Crawford, Robert Damitz, Brendan Michael Davis, Cody Michael Hodge, Michael Leland Kimmel II, Tihami Qureshi Willard, Phillip Ramsey, Daniel Joseph Thorne, Anthony Lee Young
  • Methods and compositions for the treatment of lysosomal storage diseases
    Patent number: 11898158
    Abstract: Nucleases and methods of using these nucleases for inserting a sequence encoding a therapeutic protein such as an enzyme into a cell, thereby providing proteins or cell therapeutics for treatment and/or prevention of a lysosomal storage disease.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: February 13, 2024
    Assignee: Sangamo Therapeutics, Inc.
    Inventor: Edward J. Rebar
  • ZINC FINGER FUSION PROTEINS FOR NUCLEOBASE EDITING
    Publication number: 20240043829
    Abstract: Provided herein are base editor systems comprising fusion proteins that comprise zinc finger protein and cytidine deaminase domains, as well as methods of using the base editor systems. The systems can be used to specifically alter a single base pair in a target DNA sequence.
    Type: Application
    Filed: September 24, 2021
    Publication date: February 8, 2024
    Applicant: Sangamo Therapeutics, Inc.
    Inventors: Friedrich A. Fauser, Jeffrey C. Miller, Sebastian Arangundy
  • NOVEL ZINC FINGER PROTEIN TRANSCRIPTION FACTORS FOR REPRESSING ALPHA-SYNUCLEIN EXPRESSION
    Publication number: 20240018203
    Abstract: The present disclosure provides zinc finger fusion proteins that inhibit expression of alpha-synuclein in the nervous system, and methods of using the proteins to treat Parkinsons disease, Lewy body dementia, multiple system atrophy, Alzheimers disease, and other neurodegenerative diseases.
    Type: Application
    Filed: October 1, 2021
    Publication date: January 18, 2024
    Applicant: Sangamo Therapeutics, Inc.
    Inventors: Asa Hatami, Bryan Zeitler, Lei Zhang, David Emanuel Paschon
  • ASSAYS FOR FABRY DISEASE TREATMENT
    Publication number: 20240003901
    Abstract: The disclosure provides the enzyme and non-enzyme replacement therapies for treating Fabry disease in a human subject, determined based on measuring the presence or absence of an anti-?-Galactosidase A (GLA) neutralizing antibody in a biological sample of the subject, as measured by an anti-GLA neutralizing antibody assay.
    Type: Application
    Filed: September 30, 2021
    Publication date: January 4, 2024
    Applicant: Sangamo Therapeutics, Inc.
    Inventor: Joshua Nelson HOLTER
  • Method for the treatment of mucopolysaccharidosis type I
    Patent number: 11857641
    Abstract: Described herein are methods and compositions for treating MPS I (Hurler/Hurler-Scheie/Scheie Syndrome) by administering to the subject a composition comprising a iduronidase (IDUA) polynucleotide. In one aspect, provided is a method of reducing, delaying and/or eliminating one or more of the need for additional treatment procedures, the onset, progression and/or severity of symptoms in a subject with MPS I, by administering to the subject a composition comprising a iduronidase (IDUA) polynucleotide.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: January 2, 2024
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Dale Ando, Cheryl Wong Po Foo, Sagar A. Vaidya, Shelley Q. Wang
  • Methods and compositions for regulation of transgene expression
    Patent number: 11859190
    Abstract: Nucleases and methods of using these nucleases for expressing a transgene from a safe harbor locus in a secretory tissue, and clones and animals derived therefrom.
    Type: Grant
    Filed: March 3, 2021
    Date of Patent: January 2, 2024
    Assignee: Sangamo Therapeutics, Inc.
    Inventor: Edward J. Rebar
  • Regulation of gene expression using engineered nucleases
    Patent number: 11845965
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a hematopoietic cell.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: December 19, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Jeffrey C. Miller, Edward J. Rebar
  • GENERATION OF CD4+ EFFECTOR AND REGULATORY T CELLS FROM HUMAN PLURIPOTENT STEM CELLS
    Publication number: 20230392118
    Abstract: Provided herein are improved methods and compositions for generating CD4-positive effector T cells and regulatory T cells and methods of use thereof.
    Type: Application
    Filed: October 28, 2021
    Publication date: December 7, 2023
    Applicant: Sangamo Therapeutics, Inc.
    Inventors: Helen Fong, Anthony Conway, Matthew C. Mendel
  • Engineered target specific base editors
    Patent number: 11834686
    Abstract: Described herein are DNA-editing complexes, particularly DNA-editing complexes that specifically alter a single base pair in target DNA sequence as well as methods of making and using these DNA-editing complexes.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: December 5, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Friedrich Fauser, Jeffrey C. Miller, Edward Rebar
  • METHODS FOR THE TREATMENT OF BETA-THALASSEMIA
    Publication number: 20230381225
    Abstract: Described herein are methods and compositions for treating a beta-thalassemia.
    Type: Application
    Filed: March 20, 2023
    Publication date: November 30, 2023
    Applicant: SANGAMO THERAPEUTICS, INC.
    Inventors: Weston P. Miller, IV, John Tomaro, Sagar A. Vaidya, Mark Walters
  • Engineered target specific nucleases
    Patent number: 11827900
    Abstract: Described herein are engineered nucleases comprising mutations in the cleavage domain (e.g., FokI or homologue thereof) and/or DNA binding domain (zinc finger protein, TALE, single guide RNA) such that on-target specificity is increased.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: November 28, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Jeffrey C. Miller, Edward J. Rebar
  • Methods and compositions for engineering immunity
    Patent number: 11793888
    Abstract: Nucleases and methods of using these nucleases for expressing an antibody from a safe harbor locus in a secretory tissue, and clones and animals derived therefrom.
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: October 24, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Michael C. Holmes, Brigit E. Riley
  • METHODS AND COMPOSITIONS FOR EXPRESSING PHENYLALANINE HYDROXYLASE
    Publication number: 20230323390
    Abstract: The present disclosure provides expression constructs comprising a phenylalanine hydroxylase (PAH) transgene and methods of using the constructs for treating phenylketonuria (PKU).
    Type: Application
    Filed: June 11, 2021
    Publication date: October 12, 2023
    Applicant: Sangamo Therapeutics, Inc.
    Inventor: Gustavo de Alencastro
  • TAU MODULATORS AND METHODS AND COMPOSITIONS FOR DELIVERY THEREOF
    Publication number: 20230270774
    Abstract: The present disclosure is in the field of diagnostics and therapeutics for Alzheimer's Disease.
    Type: Application
    Filed: October 13, 2022
    Publication date: August 31, 2023
    Applicants: Sangamo Therapeutics, Inc., The General Hospital Corporation
    Inventors: Annemarie Ledeboer, Bryan Zeitler, H. Steve Zhang, Sarah DeVos, Bradley T. Hyman, Susanne Wegmann
  • Methods and compositions for treating Huntington's Disease
    Patent number: 11723952
    Abstract: Disclosed herein are compositions comprising non-naturally occurring zinc finger domains, fusion proteins comprising these zinc finger domains, polynucleotides encoding these proteins, cells expressing these proteins and pharmaceutical compositions comprising these proteins or polynucleotides as well as methods of modifying an Htt gene using these compositions for treating or preventing Huntington's Disease.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: August 15, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Jeffrey C. Miller, Edward J. Rebar, H. Steve Zhang
  • Separation and quantification of empty and full viral capsid particles
    Patent number: 11725192
    Abstract: The present disclosure provides methods for the separation and quantification of empty and full viral capsids (e.g., AAV capsids) within a viral preparation, such as a viral pharmaceutical composition or drug product.
    Type: Grant
    Filed: July 12, 2020
    Date of Patent: August 15, 2023
    Assignee: SANGAMO THERAPEUTICS, INC.
    Inventors: Santoshkumar Khatwani, Zhu Pirot
  • Artificial nucleases comprising engineered cleavage half-domains
    Patent number: 11725218
    Abstract: Disclosed herein are engineered cleavage half-domains; fusion polypeptides comprising these engineered cleavage half-domains; polynucleotides encoding the engineered cleavage half-domains and fusion proteins; and cells comprising said polynucleotides and/or fusion proteins. Also described are methods of using these polypeptides and polynucleotides, for example for targeted cleavage of a genomic sequence.
    Type: Grant
    Filed: October 4, 2021
    Date of Patent: August 15, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Yannick Doyon, Jeffrey C. Miller
  • Compositions and methods for producing recombinant AAV
    Patent number: 11718834
    Abstract: Provided herein are nucleic acid constructs, host insect cells, and methods for producing recombinant AAV capsids with high potency at high yield.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: August 8, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Andrea J. Kang, Richard T. Surosky, Alex Michael Ward